Rationale for risk reduction of cardiovascular disease using homocysteine concentration in blood and plasma as biomarker: support by clinical data.
Pietrzik
K
K
Institute of Nutritional Science, Department of Pathophysiology of Nutrition, University of Bonn, Germany. k.pietrzik@uni.bonn.de
D015415:Biomarkers / Q000097:blood; D002318:Cardiovascular Diseases / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D019587:Dietary Supplements; D005492:Folic Acid / Q000097:blood / Q000378:metabolism / Q000627:therapeutic use; D006710:Homocysteine / Q000097:blood* / Q000378:metabolism; D006801:Humans; D018673:Nutrition Policy; D011736:Pyridoxine / Q000097:blood / Q000378:metabolism / Q000627:therapeutic use; D012307:Risk Factors; D014805:Vitamin B 12 / Q000097:blood / Q000378:metabolism / Q000627:therapeutic use
D015415:Biomarkers; D006710:Homocysteine; D005492:Folic Acid; D011736:Pyridoxine; D014805:Vitamin B 12